News

The director of NIDA discusses the interplay of substance use disorder and pain in patients, as well as means to assure patients are receiving evidenced-based treatment.

Lois Choi-Kain, MD, MEd, discusses the unique presentations of disease and burdens of care that impact younger patients with BPD.

The modern psychiatrist may play many roles, including as a mentor and a facilitator to social-based support.

Though patients with undifferentiated pruritus had higher serum LDH levels, these levels were not associated with an increased risk of hematologic cancer.

Prior to this new data, only 2 studies had evaluated the association between psoriasis and NAFLD in the US.

Investigators suggested that the large number of systemic therapies used when treating HS in these patients indicated referral delays or difficulties in obtaining disease control in those with moderate to severe HS.

There are several live microbiota therapeutics in development, including RBX2660.

Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.

The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.

The NIDA director reviews neuromodulation's potential role in treating patients with multiple use disorders, and the importance of patient feedback in shaping clinical research.

Rachel Talley, MD, discusses the industry-level changes needed to trainee recruitment and retention to create a psychiatry field more representative of its patient population.

Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.

The age of screening for colon cancer has decreased in recent years.

Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.

The findings show EUS-CDL is more efficient than ERCP-M with comparable short-term effectiveness and safety.

New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.

Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively

The treatment recently became the first ever FDA-approved medication for EoE.

With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.

This approval makes tapinarof cream the first and only FDA-approved steroid-free topical medication in its class.

Despite this, more than half of nurses included in this global survey were not financially compensated for their additional work.

Brent Forester, MD, MSc, discusses the confluence of biomarker and disease-targeting therapy in Alzheimer's, and the need to appropriately introduce these tools.

New research has suggested that approximately 2%-5% of patients with sarcoidosis also struggle with cardiac sarcoidosis.

The director of NIDA discusses the unprecedented impact of the pandemic on overdose deaths—and how substance use disorder care may still reach greater capability when all is said and done.

Dementia and Alzheimer's disease cases are anticipated to boom in coming decades. One expert stressed the need for improved screening and facilitation of care at the earliest stages and signs.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.

BMI did not have an association with increased risk for death in any BMI category, according to study investigators.